2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.1 - Release 2022.1
2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by CDC / Security Risk Solutions, Inc. (SRS). This guide is not an authorized publication; it is the continuous build for version 2022.1.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/security-rs/opioid-cds-r4/ and changes regularly. See the Directory of published versions
| system-version | http://snomed.info/sct|http://snomed.info/sct/731000124108/version/20250901 |
| default-canonical-version | http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation|5.3.0 |
| default-canonical-version | http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence|5.3.0 |
| default-canonical-version | CPGComputableValueSet version: 1.0.0 |
| default-canonical-version | CPGExecutableValueSet version: 1.0.0 |
| system-version | Logical Observation Identifiers, Names and Codes (LOINC) version: 3.1.0 |
| system-version | International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) version: 2.0.1 |
| system-version | Medicationrequest status version: 4.0.1 |
| default-canonical-version | CPGShareableLibrary version: 1.0.0 |
| default-canonical-version | CPGComputableLibrary version: 1.0.0 |
| default-canonical-version | CPGPublishableLibrary version: 1.0.0 |
| default-canonical-version | CPGExecutableLibrary version: 1.0.0 |
| system-version | UsageContextType version: 2.0.1 |
| system-version | CDC MME Usage Context Codes version: 3.0.0 |
| default-canonical-version | Patient version: 4.0.1 |
| system-version | RxNorm version: 3.0.1 |
| default-valueset-version | Limited life expectancy conditions version: 2022.1.1 |
| default-valueset-version | Therapies indicating end of life care version: 2022.1.1 |
| default-valueset-version | Conditions likely terminal for opioid prescribing version: 2022.1.1 |
| default-valueset-version | CDC malignant cancer conditions version: 2022.1.1 |
| default-valueset-version | Oncology specialty designations (NUCC) version: 2022.1.1 |
| default-valueset-version | Opioid misuse disorders version: 2022.1.1 |
| default-valueset-version | Substance misuse behavioral counseling version: 2022.1.1 |
| default-valueset-version | Conditions documenting substance misuse version: 2022.1.1 |
| default-valueset-version | Office Visit version: 0.2.0 |
| default-valueset-version | Opioid counseling procedure version: 2022.1.1 |
| default-valueset-version | Opioid misuse assessment procedure version: 2022.1.1 |
| default-valueset-version | Hospice Disposition version: 2022.1.1 |
| default-valueset-version | Hospice Finding version: 2022.1.1 |
| default-valueset-version | Observation Category Laboratory version: 2022.1.1 |
| default-valueset-version | Observation Category Procedure version: 2022.1.1 |
| default-valueset-version | Pain treatment plan version: 2022.1.1 |
| default-valueset-version | Pain management procedure version: 2022.1.1 |
| default-valueset-version | PDMP review procedure version: 2022.1.1 |
| default-valueset-version | PDMP data reviewed finding version: 2022.1.1 |
| default-valueset-version | Sleep disordered breathing version: 2022.1.1 |
| default-valueset-version | Opioid analgesics with ambulatory misuse potential version: 2022.1.1 |
| default-valueset-version | Extended release opioid with ambulatory misuse potential version: 2022.1.1 |
| default-valueset-version | Buprenorphine Medications version: 2022.1.1 |
| default-valueset-version | Buprenorphine and Methadone medications version: 2022.1.1 |
| default-valueset-version | Non-synthetic opioid medications version: 2022.1.1 |
| default-valueset-version | Barbiturate Medications version: 2022.1.1 |
| default-valueset-version | Benzodiazepine medications version: 2022.1.1 |
| default-valueset-version | Naloxone medications version: 2022.1.1 |
| default-valueset-version | Fentanyl-type medications version: 2022.1.1 |
| default-valueset-version | Amphetamine class medications version: 2022.1.1 |
| default-valueset-version | Methadone medications version: 2022.1.1 |
| default-valueset-version | Oxycodone Medications version: 2022.1.1 |
| default-valueset-version | Synthetic opioid medications version: 2022.1.1 |
| default-valueset-version | CNS depressant medications version: 2022.1.1 |
| default-valueset-version | All urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Non-opioid drug urine screening version: 2022.1.1 |
| default-valueset-version | Opiate specific urine drug screening tests version: 2022.1.1 |
| default-valueset-version | General opiate urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Opioid drug urine screening version: 2022.1.1 |
| default-valueset-version | Cocaine urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Phencyclidine urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Fentanyl-type urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Amphetamine-class drugs and metabolite urine tests version: 2022.1.1 |
| default-valueset-version | Cannabinoid class urine drug screening version: 2022.1.1 |
| default-valueset-version | Methadone urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Synthetic opioid urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Barbiturate urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Benzodiazepine urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Buprenorphine urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Heroin urine drug screening tests version: 2022.1.1 |
| default-valueset-version | Oxycodone urine drug screening tests version: 2022.1.1 |
| default-valueset-version | ValueSet - Medication Request Category Community version: 0.0.1 |
| default-valueset-version | Condition Clinical Status Active version: 2022.1.1 |
| default-valueset-version | ValueSet - Medication Request Status Active version: 0.0.1 |
| default-valueset-version | Encounter Diagnosis Condition Category version: 2022.1.1 |
| default-valueset-version | Problem List Condition Category version: 2022.1.1 |
| default-valueset-version | US Core Health Concern Condition Category version: 2022.1.1 |
| default-valueset-version | Sickle-cell diseases version: 2022.1.1 |
| default-canonical-version | MedicationRequest version: 4.0.1 |
| default-canonical-version | Medication version: 4.0.1 |
| default-canonical-version | Condition version: 4.0.1 |
| default-canonical-version | Observation version: 4.0.1 |
| default-canonical-version | Encounter version: 4.0.1 |
| default-canonical-version | CarePlan version: 4.0.1 |
| default-canonical-version | Procedure version: 4.0.1 |
| default-canonical-version | MedicationDispense version: 4.0.1 |
| default-canonical-version | CPGRecommendationDefinition version: 1.0.0 |
| default-canonical-version | CPGPublishablePlanDefinition version: 1.0.0 |
| default-canonical-version | Library - Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #2 - Opioid Therapy Goals Discussion version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy version: 2022.1.0 |
| default-canonical-version | Library - Recommendations #4 and #5 - Lowest Effective Dose version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #6 - Prescribe Lowest Effective Dose and Duration version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #7 - Opioid Therapy Risk Assessment version: 2022.1.0 |
| default-canonical-version | ActivityDefinition - Risk Assessment ServiceRequest version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #8 - Naloxone Consideration version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #10 - Urine Drug Testing version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #10 Patient View - Urine Drug Testing version: 2022.1.0 |
| default-canonical-version | ActivityDefinition - Urine Screening ServiceRequest version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #11 Patient View - Concurrent Use of Opioids and Benzodiazepines version: 2022.1.0 |
| default-canonical-version | Library - Recommendation #12 (patient-view) - Evidence-based Treatment for Patients with Opioid Use Disorder version: 2022.1.0 |
| default-canonical-version | Extension version: 4.0.1 |
| default-canonical-version | Element version: 4.0.1 |
| default-canonical-version | ValueSet version: 4.0.1 |
| default-canonical-version | DomainResource version: 4.0.1 |
| default-valueset-version | All Languages version: 4.0.1 |
| default-canonical-version | CDC 2022 Opioid Guidance Clinical Focus Extension version: 1.0.0 |
| default-canonical-version | CDC 2022 Opioid Guidance Data Element Extension version: 1.0.0 |
| default-canonical-version | CDC 2022 Opioid Guidance Inclusion Criteria Extension version: 1.0.0 |
| default-canonical-version | CDC 2022 Opioid Guidance exclusion Criteria Extension version: 1.0.0 |